---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-024826"
form_type: "8-K"
ticker: "ONCO"
cik: "0001782107"
company_name: "Onconetix, Inc."
filed_at: "2025-03-19T23:59:59+00:00"
generated_at: "2026-05-24T11:56:49.987494+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.2
confidence: "high"
source: SEC EDGAR
---

# Onconetix to present Proclarix clinical data at EAU congress; study of 800+ patients

## Summary
- Abstract accepted for 2025 European Association of Urology congress (March 21-24, Madrid).
- Presentation titled 'Clinical Performance of Proclarix in Ruling Out Clinically Insignificant or No Prostate Cancer.'
- Study includes >800 patients from Lillebaelt Hospital, University Hospital of Southern Denmark.
- Proclarix is a biomarker-based blood test; CEO notes potential to reduce biopsies.
- No financial terms disclosed; presentation scheduled March 23.

## SEC filing metadata
- accession: 0001213900-25-024826
- form_type: 8-K
- ticker: ONCO
- cik: 0001782107
- company_name: Onconetix, Inc.
- filed_at: 2025-03-19T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.2
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1782107/000121390025024826/0001213900-25-024826-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1782107/000121390025024826/ea0234883-8k_onconetix.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-024826
- JSON: https://secwatch.observer/filing/0001213900-25-024826.json
- Plain text: https://secwatch.observer/filing/0001213900-25-024826.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.